The DOI matches its Crossref record.
Diagnosing multiple sclerosis at a later age: more than just progressive myelopathy
Abstract
Background Multiple sclerosis (MS) is usually considered a 'young persons' disease', typically presenting between the ages of 20 and 40. In this study we review our experience with patients diagnosed at age 60 or over, with particular emphasis on patients who continue to have evidence of active inflammation despite a later onset. Methods We reviewed all cases of MS diagnosed at or over age 60 in our center over a 5-year period. We identified 111 patients and recorded their clinical and imaging characteristics using prespecified variables. Analyses were performed to describe their interval to diagnosis, clinical syndromes, imaging and laboratory characteristics. Results At the time of diagnosis, 8% of patients had a clinically isolated syndrome, 33% were in the relapsing-remitting stage, while 23% had a secondary progressive course, and 32% were primary progressive. Eighty-eight percent of patients had a brain MRI judged 'typical for MS', and 32% of all patients receiving gadolinium had enhanced lesions. Forty-six percent of patients with relapsing-remitting MS or clinically isolated syndrome exhibited gadolinium enhancement. Myelitis was the most common initial clinical syndrome, and progressive myelopathy was a common but not exclusive clinical syndrome at the time of diagnosis. Conclusions A relapsing pattern of MS is not uncommon, even in patients diagnosed over the age of 60. Active inflammation (clinical relapses and gadolinium enhancement) occurs in a significant number…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recent data suggest that some AQP4-seronegative patients with NMOSD features have antibodies reactive with MOG.
“Recent data suggest that some AQP4-seronegative patients with NMOSD features have antibodies reactive with MOG. 47-51”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [48]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 25
- 10.1111/j.1749-6632.1965.tb20235.x · DOI · Paper page
- 10.1212/WNL.33.12.1537 · DOI
- 10.1046/j.1532-5415.2001.49038.x · DOI
- 10.1007/s00415-008-0778-x · DOI · Paper page
- 10.1111/j.1468-1331.2004.01103.x · DOI · Paper page
- 10.1212/WNL.42.10.1907 · DOI
- 10.1007/s10072-004-0339-8 · DOI
- 10.1159/000117073 · DOI
- 10.1111/j.1532-5415.1984.tb05144.x · DOI
- 10.1111/j.1600-0404.1985.tb01547.x · DOI
- 10.1002/ana.1032 · DOI · Paper page
- 10.1212/WNL.46.4.907 · DOI
- 10.1136/jnnp.60.1.15 · DOI
- 10.1159/000093235 · DOI
- 10.1002/ana.10147 · DOI
- 10.1093/brain/awh714 · DOI
- 10.1016/S0002-9440(10)65218-2 · DOI
- 10.1523/JNEUROSCI.22-07-02451.2002 · DOI · Paper page
- 10.1212/WNL.56.3.422 · DOI
- 10.1212/WNL.54.9.1734 · DOI
- 10.1136/jnnp.2004.036590 · DOI
- 10.1056/NEJMoa044396 · DOI
- 10.1056/NEJMoa044397 · DOI
- 10.1212/01.WNL.0000034080.43681.DA · DOI
- 10.1016/S0140-6736(98)03334-0 · DOI
Cited by
Sorted by citations
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167
Metadata
- Authors
- Bermel, R. A., Rae-Grant, A. D., & Fox, R. J.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Bermel, Robert A
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2010-07-29
- Volume
- 16
- Issue
- 11
- Pages
- 1335-1340
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2130234762
- Cited by
- 46
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 7 · 2023: 3 · 2022: 4 · 2021: 6 · 2020: 1 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 3 · 2013: 2 · 2012: 1
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Multiple Sclerosis Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (K23NS047211)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Keywords
- multiple sclerosis, late-onset multiple sclerosis, older adults, progressive myelopathy, relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis, clinically isolated syndrome, gadolinium enhancement, brain MRI, myelitis, active inflammation
- MeSH terms
- Aged, Disability Evaluation, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Spinal Cord Diseases, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review